Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst

seekingalpha07-04

Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448558435?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg","is_english":true,"pubTime":"2024-07-04 01:09","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2448558435","market":"us","top_or_hot":-1,"title":"Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst","media":"seekingalpha","content":"<div>\n<p>Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly's new Alzheimer's drug could generate $7.1B in sales: analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 01:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales","article_id":"2448558435","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448558435","pubTimestamp":1720026557,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO. Kisunl","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4532":"文艺复兴科技持仓","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0058720904.USD":"联博国际健康护理基金A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BIIB":"渤健公司","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4007":"制药","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","ESAIY":"Eisai Co., Ltd.","BK4588":"碎股","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓","LLY":"礼来","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD"},"translate_title":"分析师：礼来公司的新阿尔茨海默氏症药物可产生$7.1 B的销售额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"ESAIY":1,"LLY":1},"content_text":"Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO. Kisunla, also known as donanemab, will be priced at $32,000 per year, with each vial costing $695.65, according to Lilly. The drug is expected to compete with Eisai (OTCPK:ESAIY) and Biogen’s (BIIB) Leqembi, which received FDA approval in 2023. According to reports, Lequembi costs around $26,500 a year. Both drugs are delivered via IV. Lilly’s Kisunla is only required to be infused every four weeks, while Leqembi is administered every two weeks, giving Lilly an advantage as far as convenience. The products are intended to lower the level of amyloid plaques in the brain, which are believed to play a major role in the development and progression of the disease. “While BMO expects Kisunla’s launch to be slow, similar to Leqembi, approval represents a meaningful expansion opportunity for the company in neuroscience,” BMO said in a note on Wednesday. Currently, Lilly’s revenue stream is dominated by diabetes medications. The company’s top-selling drug for 2023 was the diabetes medication Trulicity, with sales of $7.1B, followed by its GLP-1 diabetes drug Mounjaro, which generated sales of $5.1B. Mounjaro is also marketed for weight-loss under the name Zepbound. Lilly’s breast cancer drug Verzenio was its third best-seller, with sales of $3.9B. Lilly’s total revenue for 2023 was $34B. BMO also believes that it’s advantageous having two leading drugmakers in the Alzheimer’s market rather than just one, “given the significant infrastructure required to establish anti-amyloid therapies within the Alzheimer’s treatment paradigm.” “The Kisunla approval is actually likely to benefit both products’ sales,” BMO added. SA analyst Stephen Ayers, meanwhile, sees peak annual sales for Kisunla at between $2B and $5B. He also sees Kisunla as having the upper hand on Leqembi, due in part to its more convenient administration schedule. He noted that Lilly might also be able to learn from Biogen’s issues in launching Leqembi, giving it a second-mover advantage. “While there is a lot of uncertainty about drugs like Kisunla and Leqembi in the AD market, I believe Eli Lilly’s Kisunla is a better choice,” wrote Ayers in his latest analysis piece. “Kisunla likely adds another blockbuster to Eli Lilly’s arsenal and investors should appreciate the diversity in therapeutic indications.”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448558435"}